Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise.

Core Insights - Arcutis Biotherapeutics reported a significant third-quarter performance, achieving its first-ever positive net income and exceeding market expectations [1][2] - The company's skin treatment cream, Zoryve, generated $99.2 million in sales, marking a 122% year-over-year increase, surpassing the expected $87 million [2] - Arcutis has provided a sales guidance of $455 million to $470 million for the year, which is above the market consensus of $438.8 million [3] Financial Performance - Arcutis achieved a net income of $7.4 million, or 6 cents per share, a turnaround from a net loss of $41.5 million, or 33 cents per share, from the previous year [2] - The sales growth of Zoryve contributed to an improved gross-to-net margin, enhancing overall profitability [2] Market Reaction - Following the earnings report, Arcutis stock surged over 24% to $24.49, indicating strong investor confidence and interest [1] - The stock has recently broken out of a cup base pattern, suggesting a positive technical outlook [1]